As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the testing & diagnostics services industr...
Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market va...
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember...
What Happened? Shares of diagnostics company Guardant Health (NASDAQ:GH) fell 4.1% in the afternoon session after Co-CEO AmirAli Talasaz sold 50,000 shares o...
Guardant Health delivered a strong start to 2026, outperforming Wall Street’s revenue expectations in Q1 as robust demand across its core oncology, biopharma...
Diagnostics company Guardant Health (NASDAQ:GH) announced better-than-expected revenue in Q1 CY2026, with sales up 48.3% year on year to $301.7 million. The ...
Diagnostics company Guardant Health (NASDAQ:GH) reported Q1 CY2026 results exceeding the market’s revenue expectations, with sales up 48.3% year on year to $...
Diagnostics company Guardant Health (NASDAQ:GH) will be reporting results this Thursday after the bell. Here’s what you need to know. Guardant Health beat an...
What Happened? A number of stocks fell in the afternoon session after a proposed 2027 federal budget revealed significant spending cuts for key health agenci...
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have ou...
What Happened? Shares of diagnostics company Guardant Health (NASDAQ:GH) jumped 5.9% in the afternoon session after the company announced that real-world evi...
What Happened? Shares of diagnostics company Guardant Health (NASDAQ:GH) fell 3% in the afternoon session after major indices including the S&P 500 and Dow J...
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 wil...
CHICAGO — In a move that fundamentally reshapes the global diagnostics landscape, Abbott Laboratories (NYSE: ABT) officially completed its $21 billion acquisition of Exact Sciences (NASDAQ: EXAS) today, March 23, 2026. The closing of the deal marks the end of a high-stakes transition period and the beginning of a new era
What a fantastic six months it’s been for Guardant Health. Shares of the company have skyrocketed 46.9%, hitting $86.90. This was partly thanks to its solid ...
Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resou...
A number of stocks fell in the afternoon session after a surprisingly hot wholesale inflation report fueled investor concerns about persistent price pressures.
In a dramatic shift that has caught Wall Street’s heavy hitters off guard, the Russell 2000 index has surged to unprecedented heights in early 2026, signaling the definitive arrival of the long-awaited "catch-up" trade. As of February 26, 2026, small-cap stocks are not just participating in the market rally—
